We read with interest the excellent review on the outbreak of monkeypox (MPX) by Patauner et al. [1]. The epidemiological scenario was exhaustively described but referred to a pre-vaccination era. In fact, in August 2022, EMA's Emergency Task Force advised on use of Imvanex/Jynneos against MPX [2]. The Italian Ministry of Health advised pre-exposure vaccination of at-risk individuals identified as men who have sex with men (MSM) having multiple sexual partners, and/or group sex and/or chemsex and/or a recent diagnosis of sexually transmitted infection (STI), irrespective of HIV infection [3].
